This market research report includes a detailed segmentation of the global allergic rhinitis drugs market based on the class of drugs (antihistamines, intranasal corticosteroids, and immunotherapies), and by route of administration (oral, parenteral, and intranasal). It also outlines the market shares of key regions such as the Americas, APAC, and Europe. The key vendors analyzed in this report are AstraZeneca, GlaxoSmithKline, Meda, Merck, Sanofi, and UCB.
Technavio’s market research analysts estimate the global allergic rhinitis drugs market, to reach a market value of above $12 billion by 2020. Exposure to pollutants in the atmosphere such as vehicular emissions, pollen, or animal dander is a major cause for the rise in the incidence of allergic rhinitis. The Americas lead the global allergic rhinitis market, accounting for 42% of the overall market share. During 2014, the American College of Allergy, Asthma & Immunology conducted a study and analyzed that at least 50 million people in the US were affected with allergic rhinitis. The demand for drugs that cater to the unmet medical needs provides an opportunity for vendors to develop new safe and efficient molecules.
The new market research report from Technavio provides a breakdown and analysis of the allergic rhinitis segments by technology.
“Of late, the consumers are preferring self-medication using over-the-counter (OTC) products to treat allergic rhinitis. The changing regulatory policies have resulted in the preference for over-the-counter drugs over prescribed drugs. An individual can bug these drugs without a prescription from healthcare professionals, and also people with mild allergic rhinitis can opt for these drugs for self-medication,” says Imran Mushtaq, Industry Manager, Healthcare & Lifesciences, Technavio Research.
The antihistamine drugs are the most used drugs for allergic rhinitis and accounted for about 64% of the market share in 2015. Factors such as increased preference for complementary and alternative medicines (CAM) and over usage of off-label antihistamines are expected to drive the growth of the antihistamine drugs market. These drugs are further categorized into two segments, namely oral antihistamines and intranasal antihistamines.
Global allergic rhinitis drugs market based on class of drugs
Source: Technavio, 2016
The key players in the global allergic rhinitis drugs market are AstraZeneca, GlaxoSmithKline, Meda, Merck, Sanofi, and UCB. This market is highly competitive owing to the presence of numerous small and large drug manufacturers with varied product portfolios to treat allergic rhinitis. Therefore, to gain a competitive advantage over other companies, manufacturers in the market need to produce and market a drug that will not only treat allergic rhinitis effectively and cure it but also exhibit a high safety and efficacy profile.
A more detailed analysis is available in the Technavio report, Global Allergic Rhinitis Drugs Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
